A Phase 2 interventional study of TAK-861 and Placebo in Narcolepsy Type 1, sponsored by Takeda. Completed at 57 sites in 12 countries. Open to participants aged 16 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-01-09.
Sponsored by Takeda · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Narcolepsy by Takeda — 4 open to participants now, 6 under way, 2 of them phase 3. Narcolepsy · Takeda.
Among the 16 studies in Narcolepsy by Takeda, this one is the 3rd largest by enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2023, is one of 6 in phase 2, and was the 7th registered.
158 studies on the registry are indexed under Narcolepsy; 38 are open to participants now.
Browse Narcolepsy studies →4 of the 16 studies in Narcolepsy by Takeda are open now, in 12 countries. Recruiting first, the newest first:
Takeda · Sites in United States, Australia, China and 4 more countries
Ages 18–70
Takeda · Sites in United States, China, France and 4 more countries
Ages 18–70
Takeda · Sites in United States, Australia, Finland and 9 more countries
Ages 16–70
Takeda
Ages 18–70
By country, each count listing its studies:
Of the 30 Narcolepsy studies recruiting now, 12 (40%) set no upper age limit and 16 (53%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.
This study: 16 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 4
First in 2017; this study’s year is marked. 3 started in 2023.
This study's enrollment of 112 is above the median of 78 across 114 interventional studies indexed under Narcolepsy.
Median enrollment 95 across the 12 interventional studies, 307 across the 4 observational. Of the 10 that completed or were terminated, 9 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
5 of the studies in Narcolepsy by Takeda that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07363720Phase 3TakedaA Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy | 2026-12-17 |
| NCT06952699TakedaA Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2) | 2026-11-30 |
| NCT07299097TakedaEpidemiology of Narcolepsy Type 1 and Type 2 in Spain | 2026-12-31 |
| NCT07903220TakedaA Study About Treatment Use in Adults With Narcolepsy Type 1 (NT1) in Europe and Canada | 2027-09-30 |
| NCT07633301TakedaA Study of TAK-360 in Adults With Narcolepsy Type 1 (Narcolepsy With Cataplexy) | 2027-11-28 |
Add all 5 to your calendar (.ics) → With an account.
Among the 16 studies in Narcolepsy by Takeda, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main aim of this study is to see how TAK-861 works on symptoms of narcolepsy, including excessive daytime sleepiness and cataplexy. Approximately 100 participants will take part in the study across North America, Europe and Asia Pacific.
The treatment (TAK-861 or placebo) will be administered for 8 or 12 weeks. After this treatment period the participant will have the option to participate in a separate, long- term extension study during which all participants will be treated with TAK-861.
The drug being tested in this study is called TAK-861. This study will look at the effect of TAK-861 on improvement in narcolepsy symptoms, including excessive daytime sleepiness (EDS) and number of cataplexy episodes.
The study will enroll approximately 100 patients. Participants will be randomly assigned (by chance, like flipping a coin) to one of the five treatment groups which will remain undisclosed to the participant and study doctor during the study (unless there is an urgent medical need):
This multi-center trial will be conducted worldwide. The overall time to participate in this study is up to 23 weeks. Participants will make multiple visits to the clinic during the treatment period and then will either enroll in a long-term extension study in which all participants will receive TAK-861 or have 2 final visits 7 and 28 days after last dose of study drug for follow-up assessments.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The participant is aged 18 to 70 years, inclusive, at the time of signing the form (ICF).
Note: In Japan, participants aged 16 to 70 years, inclusive, may be included.
Exclusion Criteria:
The participant has one or more of the following psychiatric disorders:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received placebo tablets matching TAK-861, orally, twice daily (BID), from Days 1 to 56.
Drug: Placebo
Participants received TAK-861 0.5 milligrams (mg), orally, BID, from Days 1 to 56.
Drug: TAK-861
Participants received TAK-861 2 mg, orally, BID, from Days 1 to 56.
Drug: TAK-861
Participants received TAK-861 2 mg followed by 5 mg dose, orally, BID, from Days 1 to 56.
Drug: TAK-861
Participants received TAK-861 7 mg, orally, once daily (QD), from Day 1 to 56. Placebo was given as the second dose.
Drug: TAK-861 · Drug: Placebo
TAK-861 oral tablets
Placebo oral tablets matching TAK-861
Change From Baseline in the Average Sleep Latency as Determined From the MWT at Week 8
The MWT is a validated, objective measure that evaluates a participant's ability to remain awake under soporific conditions for a defined period. During each MWT session (1 session = 40 minutes), participants were instructed to sit quietly and remain awake for as long as possible. Sleep latency in each session was recorded on EEG. If no sleep was observed according to these rules, then the latency was defined as 40 minutes. The linear mixed effects model for repeated measures (MMRM) was used for analysis.
Time frame: Baseline, Week 8
Change From Baseline in Epworth Sleepiness Scale (ESS) Total Score at Week 8
The ESS is a subjective, self-administered, validated scale (scored 0 to 3) to respond to each of the 8 questions of daily life that asks participants how likely they are to fall asleep in those situations. The scores are summed to give an overall score of 0 to 24. Higher scores indicate stronger subjective daytime sleepiness, and scores below 10 are considered to be within the normal range. The MMRM was used for analysis.
Time frame: Baseline, Week 8
Weekly Cataplexy Rate (WCR) at Week 8
Participants completed a daily patient-reported sleep diary to record self-reported narcolepsy symptoms. Participants recorded episodes of cataplexy attacks in the diary. The total number of events averaged for a week were reported. WCR = (total number of cataplexy attacks over a number of non-missing diary days for a given duration/number of non-missing diary days in that duration)\*7. The generalized estimating equations (GEE) model was used for analysis.
Time frame: Week 8
Number of Participants With at Least One Treatment-emergent Adverse Event (TEAE)
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of the study intervention, whether or not the occurrence was considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (example, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE was defined as an AE with an onset that occurred after receiving study drug.
Time frame: From first dose of the study drug up to end of the study (up to 3 months)
Participants took part in the study at 33 investigative sites globally from 09 January 2023 to 14 December 2023.
| Milestone | Placebo | TAK-861 0.5 mg BID | TAK-861 2 mg BID | TAK-861 2 mg and 5 mg | TAK-861 7 mg QD |
|---|---|---|---|---|---|
| Started | 22 | 23 | 21 | 23 | 23 |
| Completed | 21 | 22 | 21 | 22 | 23 |
| Not completed | 1 | 1 | 0 | 1 | 0 |
| Withdrew: Protocol deviation | 1 | 1 | 0 | 1 | 0 |
The MWT is a validated, objective measure that evaluates a participant's ability to remain awake under soporific conditions for a defined period. During each MWT session (1 session = 40 minutes), participants were instructed to sit quietly and remain awake for as long as possible. Sleep latency in each session was recorded on EEG. If no sleep was observed according to these rules, then the latency was defined as 40 minutes. The linear mixed effects model for repeated measures (MMRM) was used for analysis.
| minutes | Placebo | TAK-861 0.5 mg BID | TAK-861 2 mg BID | TAK-861 2 mg and 5 mg | TAK-861 7 mg QD |
|---|---|---|---|---|---|
| Change From Baseline in the Average Sleep Latency as Determined From the MWT at Week 8 | -1.16 ± 2.061 | 12.49 ± 2.128 | 23.50 ± 2.042 | 25.42 ± 2.071 | 14.96 ± 1.953 |
The ESS is a subjective, self-administered, validated scale (scored 0 to 3) to respond to each of the 8 questions of daily life that asks participants how likely they are to fall asleep in those situations. The scores are summed to give an overall score of 0 to 24. Higher scores indicate stronger subjective daytime sleepiness, and scores below 10 are considered to be within the normal range. The MMRM was used for analysis.
| score on a scale | Placebo | TAK-861 0.5 mg BID | TAK-861 2 mg BID | TAK-861 2 mg and 5 mg | TAK-861 7 mg QD |
|---|---|---|---|---|---|
| Change From Baseline in Epworth Sleepiness Scale (ESS) Total Score at Week 8 | -2.50 ± 1.109 | -8.92 ± 1.085 | -13.79 ± 1.115 | -12.81 ± 1.073 | -11.29 ± 1.064 |
Participants completed a daily patient-reported sleep diary to record self-reported narcolepsy symptoms. Participants recorded episodes of cataplexy attacks in the diary. The total number of events averaged for a week were reported. WCR = (total number of cataplexy attacks over a number of non-missing diary days for a given duration/number of non-missing diary days in that duration)\*7. The generalized estimating equations (GEE) model was used for analysis.
| cataplexy attacks per week | Placebo | TAK-861 0.5 mg BID | TAK-861 2 mg BID | TAK-861 2 mg and 5 mg | TAK-861 7 mg QD |
|---|---|---|---|---|---|
| Weekly Cataplexy Rate (WCR) at Week 8 | 8.76 (5.68 to 13.51) | 4.24 (2.60 to 6.92) | 3.14 (1.65 to 5.98) | 2.48 (1.30 to 4.73) | 5.89 (3.64 to 9.53) |
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of the study intervention, whether or not the occurrence was considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (example, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE was defined as an AE with an onset that occurred after receiving study drug.
| Participants | Placebo | TAK-861 0.5 mg BID | TAK-861 2 mg BID | TAK-861 2 mg and 5 mg | TAK-861 7 mg QD |
|---|---|---|---|---|---|
| Number of Participants With at Least One Treatment-emergent Adverse Event (TEAE) | 7 | 13 | 15 | 21 | 21 |
Collected over From first dose of the study drug up to end of the study (up to 3 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/22 (0%) | 0/22 (0%) | 5/22 (22.7%) |
| TAK-861 0.5 mg BID | 0/23 (0%) | 0/23 (0%) | 11/23 (47.8%) |
| TAK-861 2 mg BID | 0/21 (0%) | 0/21 (0%) | 15/21 (71.4%) |
| TAK-861 2 mg/5 mg | 0/23 (0%) | 1/23 (4.3%) | 20/23 (87%) |
| TAK-861 7 mg QD | 0/23 (0%) | 0/23 (0%) | 20/23 (87%) |
| Event | Placebo | TAK-861 0.5 mg BID | TAK-861 2 mg BID | TAK-861 2 mg/5 mg | TAK-861 7 mg QD |
|---|---|---|---|---|---|
| Ankle fractureInjury, poisoning and procedural complications | 0/22 | 0/23 | 0/21 | 1/23 | 0/23 |
| Event | Placebo | TAK-861 0.5 mg BID | TAK-861 2 mg BID | TAK-861 2 mg/5 mg | TAK-861 7 mg QD |
|---|---|---|---|---|---|
| InsomniaPsychiatric disorders | 1/22 | 5/23 | 10/21 | 13/23 | 15/23 |
| Micturition urgencyRenal and urinary disorders | 1/22 | 5/23 | 4/21 | 12/23 | 9/23 |
| PollakiuriaRenal and urinary disorders | 1/22 | 3/23 | 7/21 | 7/23 | 12/23 |
| Salivary hypersecretionGastrointestinal disorders | 1/22 | 2/23 | 2/21 | 6/23 | 2/23 |
| HeadacheNervous system disorders | 1/22 | 1/23 | 3/21 | 2/23 | 2/23 |
| Middle insomniaPsychiatric disorders | 0/22 | 1/23 | 0/21 | 3/23 | 0/23 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 0/22 | 0/23 | 2/21 | 0/23 | 0/23 |
| Increased appetiteMetabolism and nutrition disorders | 1/22 | 0/23 | 2/21 | 1/23 | 1/23 |
| NasopharyngitisInfections and infestations | 0/22 | 0/23 | 2/21 | 2/23 | 2/23 |
| ConstipationGastrointestinal disorders | 0/22 | 0/23 | 0/21 | 0/23 | 2/23 |
Safety Analysis Set included all participants who received at least one dose of study drug.
| Age, Continuous(years) | Placebo | TAK-861 0.5 mg BID | TAK-861 2 mg BID | TAK-861 2 mg and 5 mg | TAK-861 7 mg QD | Total |
|---|---|---|---|---|---|---|
| Mean | 37.5 ± 11.86 | 32.7 ± 11.06 | 31.7 ± 11.31 | 34.7 ± 11.48 | 33.3 ± 11.94 | 34 ± 11.5 |
| Sex: Female, Male(Participants) | Placebo | TAK-861 0.5 mg BID | TAK-861 2 mg BID | TAK-861 2 mg and 5 mg | TAK-861 7 mg QD | Total |
|---|---|---|---|---|---|---|
| Female | 14 | 11 | 9 | 14 | 10 | 58 |
| Male | 8 | 12 | 12 | 9 | 13 | 54 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | TAK-861 0.5 mg BID | TAK-861 2 mg BID | TAK-861 2 mg and 5 mg | TAK-861 7 mg QD | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 3 | 2 | 1 | 0 | 2 | 8 |
| Not Hispanic or Latino | 19 | 21 | 20 | 23 | 20 | 103 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 1 | 1 |
| Race (NIH/OMB)(Participants) | Placebo | TAK-861 0.5 mg BID | TAK-861 2 mg BID | TAK-861 2 mg and 5 mg | TAK-861 7 mg QD | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 2 | 0 | 3 | 2 | 8 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 1 | 2 | 0 | 1 | 6 |
| White | 19 | 19 | 19 | 19 | 20 | 96 |
| More than one race | 0 | 1 | 0 | 1 | 0 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Average Sleep Latency From the Maintenance of Wakefulness Test (MWT)(minutes) | Placebo | TAK-861 0.5 mg BID | TAK-861 2 mg BID | TAK-861 2 mg and 5 mg | TAK-861 7 mg QD | Total |
|---|---|---|---|---|---|---|
| Mean | 6.1 ± 8.82 | 5.6 ± 7.89 | 3.9 ± 5.98 | 4.2 ± 3.63 | 3.6 ± 4.87 | 4.7 ± 6.48 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Jan 2023 to primary completion in Dec 2023, 11 months.
Results were first posted in Jan 2025, 1 year after primary completion.
Of 15 phase 2 interventional studies under Narcolepsy, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's 11 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Oveporexton